Neutropenia Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Neutropenia Pipeline Analysis report covers 23 drugs currently in different phases of development. Neutropenia means extremely low count of neutrophils in body. Neutrophils are the type of white blood cells and destroy bacteria and other organisms that cause infection. With the lack of neutrophils in the body people with neutropenia are more likely to develop infections.  Neutropenia may be congenital or may be acquired as a result of cancer and cancer treatment or due to infections such as Tuberculosis, HIV, viral hepatitis etc. There are no specific symptoms for neutropenia apart from feeling fatigue and a blood test is performed to diagnose the disease. White blood cell growth factors are generally given as treatment to increase the count of neutrophils in the body.

The report provides neutropenia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Shire, IQVIA, Sanofi and Amicus Therapeutics, Inc. among others.

Scope:

By Company

By Phase

By Molecule Type

By Region

By Route of Administration

* There may be changes in final report as per data availability.

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company Profiles
6.1. Pfizer
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Myelo Therapeutics, Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Ilkogen Ilac
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Bolder Biotechnology
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Apotex
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Adello Biologics LLC
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Biocon Ltd
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Cantex Pharmaceuticals, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Cellerant Therapeutics Inc
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Chong Kun Dang Pharmaceutical Corp
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Coherus BioSciences Inc
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Ligand Pharmaceuticals Inc
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Mycenax Biotech Inc
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Gedeon Richter plc
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Sandoz International GmbH
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. USV Pvt Ltd
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Cleveland BioLabs, Inc
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Jiangsu T-Mab Biopharma Co.,Ltd
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Microbio Co., Ltd.
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Prolong Pharmaceuticals
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. Spectrum Pharmaceuticals, Inc.
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. BeyondSpring Pharmaceuticals
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. Hangzhou Jiuyuan Gene Engineering
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Enzychem Lifesciences Corporation
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
List of Tables
List of Figures

Pfizer
Myelo Therapeutics, Inc.
Ilkogen Ilac
Bolder Biotechnology
Apotex
Adello Biologics LLC
Biocon Ltd
Cantex Pharmaceuticals, Inc.
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Coherus BioSciences Inc
Ligand Pharmaceuticals Inc
Mycenax Biotech Inc
Gedeon Richter plc
Sandoz International GmbH
USV Pvt Ltd
Cleveland BioLabs, Inc
Jiangsu T-Mab Biopharma Co.,Ltd
Microbio Co., Ltd.
Prolong Pharmaceuticals
Spectrum Pharmaceuticals, Inc.
BeyondSpring Pharmaceuticals
Hangzhou Jiuyuan Gene Engineering
Enzychem Lifesciences Corporation